Tomoki Motegi

Dr. Tomoki Motegi

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2023 in Journal of Feline Medicine and Surgery
Verified
Journal Article
Open access
FSFumitaka Shitamori
Fumitaka Shitamori
ANAyaka Nonogaki
Ayaka Nonogaki
TMTomoki Motegi
Tomoki Motegi
YMYuki Matsumoto
Yuki Matsumoto
MSMika Sakamoto
Mika Sakamoto
SMShingo Maeda
Shingo Maeda
Objectives: Autosomal dominant polycystic kidney disease (ADPKD) is a common inherited disease in cats. In most cases, the responsible abnormality is a nonsense single nucleotide polymorphism in exon 29 of the PKD1 gene (chrE3:g.42858112C>A, the conventional PKD1 variant). The aim of this study was to conduct a large-scale epidemiological study of ADPKD caused by the conventional PKD1 variant in Japan and to search for novel polymorphisms by targeted resequencing of the PKD1 using a next-generation sequencer. Methods: A total of 1281 cats visiting the Veterinary Medical Center of the University of Tokyo were included in this study. DNA was extracted from the blood of each cat. We established a novel TaqMan real-time PCR genotyping assay for the conventional PKD1 variant, and all cases were examined for the presence of this variant. Targeted resequencing of all exons of the PKD1 was performed on the DNA of 23 cats with the conventional PKD1 variant, six cats diagnosed with cystic kidneys but without this variant, and 61 wild-type normal cats. Results: Among the 1281 cats examined in this study, 23 (1.8%) harboured the conventional PKD1 variant. The odds of having the conventional PKD1 variant were significantly higher in Persian cats, Scottish Folds and Exotic Shorthairs than in the other breeds, although the number of cases in each breed was small. Furthermore, we identified four variants unique to cats with cystic kidneys that were not found in wild-type normal cats, all of which were in exon 15. In particular, two (chrE:g.42848725delC, pGly1641fs and chrE:g.42850283C>T, pArg2162Trp) were candidate variants. Conclusions and relevance: This study revealed that the conventional PKD1 variant was prevalent in Scottish Fold, Persian and Exotic Shorthair breeds in Japan, and variants in exon 15 of PKD1, in addition to the conventional variant in exon 29, would be key factors in the pathogenesis of ADPKD in cats.

14 October 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
HOHiroki Ozawa
Hiroki Ozawa
KTKazuki Takahashi
Kazuki Takahashi
TMTomoki Motegi
Tomoki Motegi
JJJustine Jacobi
Justine Jacobi
ABAtrayee Bhattarchya
Atrayee Bhattarchya
DKDonald Kufe
Donald Kufe
Purpose: Treatment of pancreatic ductal adenocarcinoma (PDAC) has been advanced by the development of KRAS inhibitors. Despite this progress, PDAC invariably develop resistance to these agents through multiple mechanisms. In this study, we investigated the role of the oncogenic MUC1-C (M1C) protein in mediating the resistance of PDAC cells to KRAS inhibition. Experimental Design: Three PDAC KRAS G12D–mutant cell lines, as well as patient-derived KRAS inhibitor–resistant organoids and patient-derived xenograft models, were investigated in these studies. An anti-M1C antibody–drug conjugate (ADC) was evaluated for in vitro and in vivo activity. Tumors from patients with PDAC were studied by single-cell RNA sequencing and IHC staining. Results: The MUC1 gene is upregulated in PDAC KRAS G12D–mutant tumors. We report that treatment of PDAC cells with the KRAS G12D inhibitor MRTX1133 is associated with the induction of the M1C protein. Mechanistically, KRAS G12D inhibition induces M1C by activation of an M1C/NF-κB p65 autoinductive pathway. Our results further demonstrate that M1C drives resistance to MRTX1133 by activating the inflammatory IFN type I pathway. Targeting M1C genetically and pharmacologically thereby reverses MRTX1133 resistance and is synergistic in combination with MRTX1133 treatment. Of translational significance, we demonstrate that an anti-M1C ADC is highly effective against MRTX1133-resistant PDAC KRAS G12D cell lines and patient-derived organoid and patient-derived xenograft models. Conclusions: These findings demonstrate that M1C confers resistance of PDAC to KRAS G12D inhibition and identify M1C as a potential target for ADC treatment of patients with PDAC who are refractory to KRAS inhibitors.

8 August 2025 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
TMTomoki Motegi
Tomoki Motegi
RFRei Fukuoka
Rei Fukuoka
YTYuzo Tsuyuki
Yuzo Tsuyuki
DNDai Nagakubo
Dai Nagakubo
SMShingo Maeda
Shingo Maeda
YMYasuyuki Momoi
Yasuyuki Momoi
Antimicrobial resistance is an increasing concern in companion animal practice; however, effective mitigation strategies in veterinary referral hospitals remain underexplored. This study investigated whether antimicrobial stewardship interventions guided by hospital-specific resistance patterns and prescribing data could improve resistance outcomes in a secondary care veterinary setting. Using data from 2016 to 2018 at the University of Tokyo Veterinary Medical Center, a targeted intervention was developed and implemented in early 2019, and its impact was evaluated until 2024. The intervention included Gram staining-based presumptive pathogen estimation, antibiogram-guided antimicrobial selection, clinician education, and regular feedback on prescribing practices. By 2020, overall antimicrobial use had reduced by over 50%, with marked reductions in the use of carbapenems and fluoroquinolones. By 2022, the prevalence of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. decreased from 53% to 24% and 78% to 7%, respectively. However, methicillin-resistant staphylococci remained prevalent in approximately 50% of cases. These findings suggest that hospital-tailored antimicrobial stewardship programs may be associated with meaningful reductions in resistance among gram-negative pathogens, although causality cannot be confirmed due to the observational study design. Moreover, additional strategies are necessary to address persistent resistance in gram-positive organisms.

Verified
Journal Article
Open access
PDF file
MKMizuki Kusumoto
Mizuki Kusumoto
MJMakoto Jitsuiki
Makoto Jitsuiki
TMTomoki Motegi
Tomoki Motegi
KHKazuki Harada
Kazuki Harada
Flomoxef (FMX) may be a potential alternative to carbapenems for dogs infected with Enterobacterales-producing extended-spectrum β-lactamase (ESBL-E). However, the appropriate dosage of FMX in dogs with ESBL-E infections has yet to be established. This study was carried out to establish appropriate treatment regimens for FMX against ESBL-E infections in dogs using a pharmacokinetics–pharmacodynamics (PK–PD) approach. Five dogs were intravenously administered at a bolus dose of FMX (40 mg/kg body weight). Serum concentrations of FMX were calculated with high-performance liquid chromatography-tandem mass spectrometry, and then applied to determine PK indices based on a non-compartmental model. The cumulative fraction of response (CFR) was estimated based on the dissemination of minimum inhibitory concentrations among wild-type ESBL-E from companion animals. From the results, the dosage regimens of 40 mg/kg every 6 and 8 h were estimated to attain a CFR of >90% for wild-type isolates of ESBL-producing Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis for dogs. By contrast, all regimens had a CFR of <80% for ESBL-producing Enterobacter cloacae. Our results indicated that dosage regimens of 40 mg/kg FMX every 6 and 8 h can be a non-carbapenem treatment for canine infections of ESBL-producing Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis, but not for those of ESBL-producing Enterobacter cloacae.

17 March 2022 in Veterinary and Comparative Oncology
Verified
Journal Article
Closed access
MHMiyuki Hirabayashi
Miyuki Hirabayashi
JCJames K. Chambers
James K. Chambers
ATAkiyoshi Tani
Akiyoshi Tani
HTHirotaka Tomiyasu
Hirotaka Tomiyasu
TMTomoki Motegi
Tomoki Motegi
KUKazuyuki Uchida
Kazuyuki Uchida